CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 261 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,514,898 | +4.9% | 899,478 | +20.6% | 0.01% | 0.0% |
| Q2 2023 | $10,023,297 | -25.6% | 745,781 | -8.2% | 0.01% | -27.3% |
| Q1 2023 | $13,466,375 | -13.8% | 812,206 | -3.3% | 0.01% | -15.4% |
| Q4 2022 | $15,629,599 | +60.3% | 840,301 | +10.5% | 0.01% | +44.4% |
| Q3 2022 | $9,753,000 | +120.2% | 760,174 | +20.3% | 0.01% | +125.0% |
| Q2 2022 | $4,430,000 | +54.7% | 631,904 | +83.0% | 0.00% | +100.0% |
| Q1 2022 | $2,863,000 | +91.9% | 345,348 | +56.7% | 0.00% | +100.0% |
| Q4 2021 | $1,492,000 | +68.6% | 220,424 | +32.0% | 0.00% | 0.0% |
| Q3 2021 | $885,000 | +79.9% | 167,041 | +95.3% | 0.00% | – |
| Q2 2021 | $492,000 | +151.0% | 85,544 | +101.6% | 0.00% | – |
| Q1 2021 | $196,000 | +56.8% | 42,430 | +13.5% | 0.00% | – |
| Q4 2020 | $125,000 | +20.2% | 37,399 | +7.3% | 0.00% | – |
| Q3 2020 | $104,000 | +19.5% | 34,866 | +86.0% | 0.00% | – |
| Q2 2020 | $87,000 | – | 18,747 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |